New Influenza Vaccine Shows Promise for Older Adults in Lancet Study

A pivotal Phase 3 study, published in The Lancet Infectious Diseases, demonstrates the benefits of CSL Seqirus's MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) for older adults. The vaccine combines three proven approaches to enhancing protection against influenza, offering important new evidence for healthcare professionals and policymakers.